Financial Performance - Revenue for Q3 2024 was ¥232,942,532.04, a decrease of 41.06% compared to the same period last year[3] - Net profit attributable to shareholders was -¥31,767,471.51, representing a decline of 167.48% year-over-year[3] - Basic earnings per share for Q3 2024 was -¥0.0154, down 165.52% from the same period last year[3] - The company experienced a 40.89% decline in revenue for the first nine months of 2024 compared to the same period in 2023, primarily due to decreased sales of composite raw materials and pharmaceutical intermediates[7] - Total operating revenue for Q3 2024 was ¥854,289,240.97, a decrease of 40.9% compared to ¥1,445,366,591.95 in the same period last year[16] - The net profit for Q3 2024 was -26,889,704.70 CNY, a significant decline compared to the net profit of 23,962,311.35 CNY in Q3 2023[17] - The total profit for the quarter was -23,697,483.58 CNY, a significant drop from the profit of 41,306,414.75 CNY in the previous year[17] - The company incurred a total operating profit loss of -20,299,504.02 CNY, compared to a profit of 35,816,355.50 CNY in Q3 2023[17] - The total comprehensive income for Q3 2024 was -111,902,457.20 CNY, a stark contrast to the comprehensive income of 77,827,636.21 CNY in the same quarter last year[18] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥75,814,240.22, an increase of 434.97% compared to the previous year[3] - The company reported a significant increase in cash flow from operating activities, primarily due to increased net sales of goods[8] - The company's cash and cash equivalents at the end of the period amounted to 668,368,156.84 RMB, down from 744,349,595.87 RMB at the beginning of the period[13] - The accounts receivable decreased from 109,154,136.75 RMB at the beginning of the period to 91,011,769.02 RMB at the end[13] - Inventory decreased from 691,603,264.38 RMB at the beginning of the period to 648,344,562.54 RMB at the end[13] - The company’s cash and cash equivalents at the end of the period were 453,787,274.52 CNY, an increase from 275,147,122.98 CNY at the end of the previous year[20] Liabilities and Equity - Total assets as of September 30, 2024, were ¥5,394,092,979.86, a decrease of 1.55% from the end of the previous year[3] - Current liabilities increased to ¥626,942,140.73, up 3.4% from ¥603,301,011.78 in the previous quarter[15] - The total equity attributable to shareholders decreased to ¥4,725,838,323.30 from ¥4,836,045,778.17, a decline of 2.3%[15] - The company’s total liabilities increased to ¥695,743,689.66 from ¥669,054,673.06, an increase of 4.2%[15] Investments and Future Projects - Investment activities generated a net cash outflow of -¥26,128,770.00, a decrease of 170.04% year-over-year, mainly due to increased financial management expenditures[8] - The company has invested in a lithium ore exploration and processing project in Nigeria, with the first beneficiation plant's equipment debugging nearly completed and trial production set to begin in Q4[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,562[9] - The largest shareholder, Shuai Fangwen, holds 41.38% of the shares, amounting to 853,574,906 shares, with 640,181,179 shares pledged[9] - The company has a total of 640,181,179 shares under pledge conditions, representing a significant portion of the largest shareholder's holdings[9] Research and Development - Research and development expenses for Q3 2024 amounted to ¥34,116,241.19, a decrease of 16.6% compared to ¥40,831,111.21 in the previous year[16] Other Information - The third quarter report of Hunan Erkang Pharmaceutical Co., Ltd. is unaudited[21] - The company will implement new accounting standards starting in 2024, affecting the financial statements from the beginning of the year[21] - No specific performance metrics or user data were provided in the report[21] - Future outlook and performance guidance were not detailed in the report[21] - There were no mentions of new products or technology developments in the report[21] - Market expansion and acquisition strategies were not discussed in the report[21] - Other new strategies were not highlighted in the report[21] - The report does not include any financial figures or percentage changes[21] - The board of directors presented the report without any additional commentary[21] - The report is part of the company's ongoing financial disclosures[21]

截至本公告披露日，李海一先生未持有公司股份，李海一先生在原定任期内 和任期届满后六个月内将继续遵守《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股份》等法律法规对于离任监 事股份管理的相关规定。李海一先生不存在应当履行而未履行的承诺事项。 李海一先生在担任公司监事期间恪尽职守、勤勉尽责、忠实履行监事义务， 公司及公司监事会对李海一先生在任职期间为公司所做的贡献表示衷心感谢！ 特此公告。 证券代码：300267 证券简称：尔康制药 公告编号：2024-019 湖南尔康制药股份有限公司 关于监事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）监事会于近日收到公司非 职工代表监事李海一先生提交的书面辞职报告。李海一先生因个人原因申请辞去 公司第五届监事会非职工代表监事职务，辞职后，李海一先生将不在公司担任任 何职务。 李海一先生担任监事的原任期届满之日为 2025 年 11 月 13 日。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业 ...

Financial Performance - In the first half of 2024, the company's traditional Chinese medicine products achieved revenue of 4006.49 million yuan, a year-on-year increase of 389.56% [2] - In the first half of 2024, the company's excipients achieved revenue of 47805.62 million yuan, accounting for 76.94% of total revenue [4] - In the first half of 2024, the company's modified starch and starch capsule series products achieved revenue of 2974.14 million yuan, a year-on-year increase of 112.97% [4] R&D and Innovation - In the first half of 2024, the company's R&D investment was 2119.59 million yuan [2] - In the first half of 2024, the company obtained 12 patents, including 1 invention patent and 11 utility model patents [3] - The company is actively exploring the use of AI technology to advance the research and development of excipients, RDC drugs, and biosynthetic drugs [3][4] Strategic Projects and Partnerships - The company's wholly-owned subsidiary, Erkang Mining, has completed the construction of the first beneficiation plant in Nigeria and is accelerating equipment debugging [4][5][6] - The company is in discussions with AI technology companies and nuclear drug R&D and production companies to leverage its resource advantages [3][4] Market and Policy Response - The company is closely monitoring industry policies and trends, and will adjust its business and management strategies accordingly to mitigate risks [3] - The company is actively developing and maintaining multiple market channels, exploring new internet-based promotion and operation models [2] Future Plans and Outlook - The company plans to further optimize products and services, stabilize existing markets, and expand into new markets [4] - The company is considering the use of AI technology to drive long-term and sustainable development [3] - The company is accelerating the debugging of equipment at its beneficiation plant in Nigeria, aiming to start production as soon as possible [4][5][6]

编制单位：湖南尔康制药股份有限公司 单位：人民币万元 | | | 占用方与上 | 上市公司核算的 | 2024 年期初往 | 2024 年 1-6 月往来累 | 2024 年 1-6 月往 | 2024 年 1-6 | 2024 年 6 月 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | | | 计发生金额（不含利 | 来资金的利息 | 月偿还累计 | 末往来资金 | | 占用性质 | | | | 联关系 | 会计科目 | 来资金余额 | 息） | （如有） | 发生金额 | 余额 | 成原因 | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人 | | | | | | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥621,346,708.93, a decrease of 40.83% compared to ¥1,050,160,519.66 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥6,300,155.19, down 87.87% from ¥51,950,756.08 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was ¥2,264,705.88, a decline of 90.55% compared to ¥23,957,372.01 in the same period last year[10]. - The basic earnings per share were ¥0.0031, a decrease of 87.70% from ¥0.0252 in the same period last year[10]. - The diluted earnings per share were also ¥0.0031, reflecting the same percentage decrease as basic earnings per share[10]. - The company's revenue for the pharmaceutical sector was CNY 607,914,905.18, a decrease of 40.94% year-over-year, with a gross margin of 30.43%[29]. - The company reported a total comprehensive income of CNY 45,231,142.85 for the first half of 2024, compared to CNY 29,304,534.65 in the previous year, marking a 54.3% increase[95]. Cash Flow and Assets - The net cash flow from operating activities increased by 148.54% to ¥127,628,976.65 from ¥51,351,223.74 in the previous year[10]. - The total assets at the end of the reporting period were ¥5,428,013,634.69, a decrease of 0.93% from ¥5,479,068,857.74 at the end of the previous year[10]. - The net cash flow from operating activities turned positive at CNY 169.54 million, compared to a negative CNY 178.64 million in the first half of 2023[98]. - The total cash inflow from financing activities was CNY 457,700,000.00, significantly higher than CNY 115,550,895.10 in the same period last year[97]. - The company's cash and cash equivalents at the end of the period stood at CNY 574,365,150.97, an increase from CNY 410,352,463.46 at the end of the previous year[97]. Investments and R&D - The company obtained 12 patents in the first half of 2024, including 1 invention patent and 11 utility model patents, highlighting its commitment to R&D[23]. - The company is committed to increasing R&D investments to enhance innovation and quickly translate research outcomes into market competitiveness[16]. - Research and development expenses amounted to CNY 21,195,856.15, down 7.83% compared to the previous period[28]. - The company has developed a stable and reliable path for the research and industrialization of injectable excipients, which won the second prize in the Hunan Provincial Science and Technology Progress Award for 2022[23]. Market and Product Development - In the first half of 2024, the company focused on the production and sales of excipients, active pharmaceutical ingredients (APIs), and finished drugs, with major excipient products including medicinal ethanol and modified starch[14]. - The company is actively adapting its business strategies in response to market changes and is focused on optimizing its asset and product structure[16]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[175]. - New product launches are expected to contribute an additional $50 million in revenue by the end of 2024[175]. Environmental and Social Responsibility - The company has a wastewater treatment facility with a design capacity of 800m³/d, which operates within emission limits and has no reported exceedances[52]. - The company's environmental protection expenditure and related environmental protection tax payments totaled CNY 6.7337 million in the first half of 2024[54]. - The company donated CNY 4.063 million worth of medicines for a public welfare initiative in July 2024[55]. Risk Management - The company has implemented strict risk management measures for foreign exchange hedging and commodity futures hedging to mitigate operational and market risks[44]. - The company is facing raw material price volatility risks due to macroeconomic factors, and it aims to strengthen market monitoring and inventory management to mitigate these risks[46]. - The company has developed a hedging management system to address foreign exchange risks associated with its increased demand for raw materials[46]. Shareholder Information - The annual shareholders' meeting had a participation rate of 51.18% on May 17, 2024[49]. - The company does not plan to distribute cash dividends or issue bonus shares for the half-year period[50]. - The total number of common shareholders at the end of the reporting period was 41,799[74]. Legal and Compliance - There were 8 main lawsuits involving a total amount of CNY 63.3564 million, with 2 cases won and 6 cases settled through mediation[57]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[56]. - There were no significant related party transactions during the reporting period[58]. Corporate Governance - The company has a robust internal management and control system to protect shareholder rights and ensure transparency[54]. - The company has not undergone any changes in its controlling shareholder during the reporting period[80]. - The financial statements of Hunan Erkang Pharmaceutical Co., Ltd. comply with accounting standards and accurately reflect the company's financial status, operating results, and cash flows[116].

湖南启元律师事务所 关于湖南尔康制药股份有限公司 2023年年度股东大会的 法律意见书 二0二四年五月 湖南启元律师事务所 关于湖南尔康制药股份有限公司 2023 年年度股东大会的法律意见书 致：湖南尔康制药股份有限公司 湖南启元律师事务所接受湖南尔康制药股份有限公司（以下简称"公司"） 的委托，指派律师出席了公司 2023 年年度股东大会（以下简称"本次股东大会"）， 对会议进行现场律师见证，并出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》等法律、 法规和规范性文件以及《湖南尔康制药股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，出具本法律意见书。 本律师出具本法律意见书基于公司已作出如下承诺：所有提供给本律师的文 件的正本以及经本律师查验与正本保持一致的副本均为真实、完整、可靠。 为出具本法律意见书，我们依法审核了公司提供的下列资料： 1 、 公 司 于 2024 年 4 月 25 日 发 布 在 深圳证券交易所网站 （http://www.szse.cn）上的公司第五届董事会第 ...

证券代码：300267 证券简称：尔康制药 公告编号：2024-015 湖南尔康制药股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票与网络投票相结合的方式 3、召开时间： 现场会议时间：2024 年 5 月 17 日（星期五）下午 14：30 网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 5 月 17 日上午 09:15-09:25、09:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年 5 月 17 日 9:15--15:00 期间的任意时间。 4、股权登记日：2024 年 5 月 10 日（星期五） 5、现场会议召开地点：公司会议室（湖南省长沙市浏阳工业园北园开元大 道工业路一号湖南尔康制药股份有限公司会议室） 6、现场会议主持人 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 275,789,340.20, a decrease of 49.57% compared to CNY 546,925,468.79 in the same period last year[4]. - Net profit attributable to shareholders was CNY 2,901,461.74, down 88.87% from CNY 26,078,945.63 year-on-year[4]. - Operating income decreased by CNY 27,113,620.00, or 49.57%, primarily due to delays in the import of raw materials and a decline in sales of pharmaceutical intermediates[10]. - Total operating revenue for Q1 2024 was ¥275,789,340.20, a decrease of 49.6% compared to ¥546,925,468.79 in the same period last year[26]. - Net profit for Q1 2024 was -¥285,701.09, a significant decline from ¥20,455,494.16 in Q1 2023[27]. - The company reported a comprehensive income total of -¥34,221,597.97 for Q1 2024, compared to -¥2,360,585.01 in the previous year[28]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.0014, down from ¥0.0126 in Q1 2023[28]. Cash Flow - The net cash flow from operating activities improved to CNY 10,699,220.82, a significant increase of 108.68% compared to a negative cash flow of CNY -123,203,775.36 in the previous year[4]. - Cash inflows from operating activities totaled ¥296,255,671.71, compared to ¥610,092,589.46 in Q1 2023, reflecting a decrease of 51.5%[29]. - Cash outflows from operating activities were ¥285,556,450.89, down from ¥733,296,364.82 year-over-year[29]. - The net cash flow from investment activities was -200,634,546.56 CNY, compared to -49,235,087.06 CNY in the previous year[30]. - Cash inflow from financing activities totaled 307,844,027.78 CNY, significantly higher than 65,550,895.10 CNY in the same period last year[30]. - The net cash flow from financing activities was 154,886,859.29 CNY, contrasting with a negative flow of -170,401,976.48 CNY in the previous year[30]. - The net increase in cash and cash equivalents was -40,894,504.26 CNY, compared to -345,705,692.65 CNY in the previous year[30]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,461,856,952.50, a slight decrease of 0.31% from CNY 5,479,068,857.74 at the end of the previous year[4]. - The total current liabilities rose to RMB 620,227,763.04 from RMB 603,301,011.78, representing an increase of approximately 2.5%[23]. - The total liabilities amounted to ¥685,980,422.61, an increase from ¥669,054,673.06 in the previous quarter[27]. - The company's cash and cash equivalents decreased to RMB 535,043,558.26 from RMB 744,349,595.87, reflecting a decline of approximately 28.2%[22]. Investments and Research - The company experienced a 307.50% increase in cash outflow from investing activities, totaling CNY -20,063,450.00, mainly due to increased financial investment outflows[12]. - The company reported a total of 7 new authorized patents related to traditional Chinese medicine production processes and equipment during the reporting period[21]. - A new bronchodilator and cough relief injection product has been submitted for registration and is currently in the inspection phase[21]. - The company is actively advancing the research of an anti-heart failure drug and has submitted supplementary materials for pre-listing communication[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 48,671, with the largest shareholder holding 41.38% of the shares[13]. Accounting and Auditing - The company did not undergo an audit for the first quarter report[31]. - The company implemented new accounting standards starting in 2024, affecting the financial statements[31].

目 录 | 一、审计报告……………………………………………………… 第 1—5 页 | | --- | | 二、财务报表……………………………………………………… 第 6—13 页 | | （一）合并资产负债表…………………………………………… 第 6 页 | | （二）母公司资产负债表………………………………………… 第 7 页 | | （三）合并利润表………………………………………………… 第 8 页 | | （四）母公司利润表……………………………………………… 第 9 页 | | （五）合并现金流量表……………………………………………第 10 页 | | （六）母公司现金流量表…………………………………………第 11 页 | | （七）合并所有者权益变动表……………………………………第 12 页 | | （八）母公司所有者权益变动表…………………………………第 13 页 | | 三、财务报表附注……………………………………………… 第 14—105 页 | | 四、附件………………………………………………………… 第 106—109 页 | | (一) 本所营业执照复印件…………………………………… ...

第一条 为维护湖南尔康制药股份有限公司（以下简称"公司"）、股东和 债权人的合法权益， 规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券 法》）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。公 司系由原湖南尔康制药有限公司依法整体变更设立，在长沙市市场监督管理局 注册登记，取得营业执照。 湖南尔康制药股份有限公司 章程 二〇二四年四月 | | = | | --- | --- | | I | 10 | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | 第二节 | 股东大会的一般规定 10 | | 第三节 | 股东大会的召集 13 | | 第四节 | 股东大会的提案与通知 15 | | 第五节 | 股东大会的召开 16 | | 第六节 | 股东大 ...